Clinical trial
A Phase II, Open-Label, Single Arm Decentralized Home-Based Approach Study to Evaluate the Efficacy and Safety of Alectinib in Locally-Advanced or Metastatic ALK-Positive Solid Tumors
NCT04644315 is registered in ClinicalTrials.gov with Hoffmann-La Roche as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase II, Open-Label, Single Arm Decentralized Home-Based Approach Study to Evaluate the Efficacy and Safety of Alectinib in Locally-Advanced or Metastatic ALK-Positive Solid Tumors
- Lead sponsor
- Hoffmann-La Roche
- Phase
- Phase 2
- Overall status
- Terminated
- Start date
- May 24, 2021
- Completion date
- May 16, 2022
- Enrollment
- 1 (actual)
- Sites
- 29
Conditions
As the registry lists them; a condition with its own page is linked.
brain neoplasms, bronchial neoplasms, carcinoma, bronchogenic, central nervous system, cholangiocarcinoma, colonic diseases, colorectal neoplasms, digestive system diseases, digestive system neoplasms, gastrointestinal diseases, gastrointestinal neoplasms, head and neck neoplasms, intestinal diseases, intestinal neoplasms, lymphoma, large-cell, anaplastic, melanoma, neoplasms, neoplasms by site, neuroendocrine tumors, ovarian neoplasms, pancreatic neoplasms, respiratory tract diseases, respiratory tract neoplasms, salivary gland neoplasms, sarcoma, thoracic neoplasms, thyroid cancer, papillary, thyroid neoplasms